Background {#Sec1}
==========

Antineoplastic drugs are among the therapeutic classes the most involved in drug related death due to their narrow therapeutic index, their high level of toxicity and the frailty of treated patients \[[@CR1], [@CR2]\]. Considered as high-risk medications, they require expertise from prescription to administration. Many actions are undertaken by pharmacists to ensure the safe management of injectable antineoplastics: centralized reconstitution, computerization, and strict prescription protocols. It is recognized that pharmacists play a crucial role in the safe use of antineoplastic drugs \[[@CR3]\]. However, despite these security measures, there is always a residual risk of error, justifying the requirement for pharmaceutical analysis of injectable antineoplastic prescriptions.

In a hospital, the Chemotherapy Preparation Unit (CPU) aims at ensuring the safety of the preparation of injectable antineoplastic drugs under the supervision of a pharmacist. This centralized service can implement the systematic pharmaceutical analysis of injectable antineoplastic prescriptions to detect Drug Related Problems (DRPs), and to carry out Pharmacist Interventions (PIs) in collaboration with prescribers \[[@CR3], [@CR4]\]. A DRP is defined as an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes \[[@CR5]\]. A PI was defined as any action initiated by a pharmacist that directly resulted in a change in a patient's therapeutic management \[[@CR6], [@CR7]\]. If accepted, a PI leads to the modification of patient's therapeutic management \[[@CR6]\].

Such modifications may have clinical consequences for patients: in the most severe cases PIs can prevent hospitalization for chemotherapy toxicity, permanent disability such as renal failure, or paresthesia, especially by detecting dosage problems or contraindications \[[@CR8]--[@CR10]\]. In others cases PIs can improve quality of life, patient satisfaction and adherence with counseling \[[@CR11]\]. Taking into account the high direct cost of injectable antineoplastics PIs may have economic impact with cost savings: by dosage adjustments or by drug waste minimization with rounding of drug dosages and selection of the most convenient vial size \[[@CR12]\]. PIs can also generate cost avoidance due to the prevention of adverse drug events: according to a study, the mean cost avoidance generated by a PI was 166€ \[[@CR13], [@CR14]\]. PIs may have also organizational impacts: pharmacists can engage actions to improve the quality of care process from the perspective of healthcare providers to optimize preparation and administration workflow \[[@CR15], [@CR16]\].

The French Society of Clinical Pharmacy (SFPC) developed and validated a multidimensional tool for assessing the whole impact of PIs, named CLEO (**CL**inical, **E**conomic, and **O**rganizational) (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR17], [@CR18]\]. The CLEO tool includes three independent dimensions to evaluate clinical, economic and organizational impact of PIs to describe the whole impact of PI. The clinical dimension focuses on impact related to the patient's well-being from the patient's perspective: averted damages, improved quality of life, and improved adherence. The economic dimension assesses the immediate impact of the PI on the current costs of therapy from the institution's perspective. The organizational dimension evaluates the impact on the process of care, focusing on the view of the health care professionals: reduced time expenditures, decreased work load, improved work place safety, and simplified collaborations. This tool was also translated and validated a the German version \[[@CR19]\]. Fig. 1The CLEO tool

Other studies performed have evaluated clinical and economic impact of PIs, but to date, no oncohaematology studies have described the impact of PIs using a multidimensional approach, taking into account clinical, economic and organizational dimensions.

This study aims at describing the clinical, economic, and organizational impacts of PIs performed by pharmacists in the CPU of a French University Hospital.

Methods {#Sec2}
=======

Setting {#Sec3}
-------

A 10-week observational study in the CPU of the 2000-bed Grenoble Alpes University Hospital (France) was conducted. About 40,000 injectable antineoplastic preparations are produced per year.

A Computerized Provider Order Entry (CPOE) system is used for the prescription of injectable antineoplastics. Prescriptions are made by senior physicians or medicine residents according to standardized protocols that have been previously validated by both pharmacists and physicians. These protocols include: drugs, doses, administration modalities (route, infusion time, solvent), and required premedication. The protocol can concern the prescription of only one injectable antineoplastic or a combination of injectable antineoplastics, for one or more days. When the prescription has been electronically signed, it's automatically transmitted in the software module for pharmacist analysis and preparation.

The prescription is analyzed at the CPU by a senior pharmacist or a trained pharmacy resident prior to administration. For each new prescription, pharmaceutical analysis includes: adequacy of the prescription with the treatment determined during a multidisciplinary cancer board, conformity of the prescribed protocol with the diagnosis and guidelines, doses, and appropriate patient's characteristics. Pharmacists access the patient's medical history through the hospital's electronic medical record system. For prescription renewal, pharmacists verified: the patient's pathophysiological data, cycle duration and number of courses, the previous prescription (drug, dose reduction, comment, and biological data if necessary). The CPOE automatically calculates the body surface area and doses.

When a DRP is identified, the pharmacist (senior or resident) of the CPU calls the medical staff to propose a PI. Finally, when the PI has been discussed with the medical staff, a preparation sheet is sent to pharmacy technicians to prepare chemotherapies.

Data collection {#Sec4}
---------------

All consecutive PIs concerning injectable chemotherapy prescriptions in inpatients units (medical oncology and hematology) and outpatient units (medical oncology including thoracic and gastro-intestinal cancer, hematology, radiotherapy) were collected, leading to 237 PIs relating to 185 patients over ten weeks.

PIs were retrospectively recorded using the electronic medical record system, generating a information report including: patients' characteristics (sex, age, weight, height and body surface area), medical history, cancer drugs and cancer protocols used, a description of the DRP and PI according to the classification of the SFPC, and whether or not it was accepted by the physician \[[@CR7]\]. These anonymized reports were provided to expert panels for assessment.

Assessment of the impact of pharmaceutical interventions {#Sec5}
--------------------------------------------------------

Using the CLEO tool, the clinical, economic and organizational consequences of each PI was assessed by consensus in one of four multidisciplinary expert panels (medical oncology/radiotherapy, hematology, hepato-gastroenterology, and pneumology) \[[@CR17]\]. Each panel consisted of four people: a specialist physician, a pharmacovigilance expert, a clinical pharmacist and a CPU pharmacist. The CLEO tool has three independent dimensions: clinical impact of the PI from the patient's perspective, economic impact of the PI from the hospital's perspective, and organizational impact of the PI from the healthcare provider's perspective (Fig. [1](#Fig1){ref-type="fig"}). Each dimension of the CLEO tool has several numeric levels, with both negative, zero, positive and values, and an open level "non-determined". The CLEO tool and 12 examples of assessments were provided to the expert panel before any PI evaluation. After the presentation of each PI by the meeting moderator, each expert independently scored clinical, economic and organizational impacts of the PI prior to discussion to reach an expert consensus.

Economic analysis {#Sec6}
-----------------

Quantifying cost savings related to direct antineoplastic costs was determined by a complementary evaluation to the CLEO tool. Cost savings were determined by listing all PIs with a positive economic impact according to the expert panel assessment using the CLEO tool (e.g. trastuzumab 6 mg/kg instead of trastuzumab 8 mg/kg). Similarly, increased costs were calculated from all PIs having a negative economic impact according to the CLEO tool (e.g. trastuzumab 6 mg/kg instead of trastuzumab 2 mg/kg). This quantitative evaluation of savings or additional costs was conducted from the hospital's perspective. It took into account the cost of injectable antineoplastics including value added tax but excluded the cost of solvents, diluents, and sterile medical devices used for preparation. Costs were calculated only for the treatment course concerned by the accepted PI, assuming that a PI has an impact only on one course. Cost savings were calculated based on the real costs of the PI accepted by the prescriber.

Statistical analysis {#Sec7}
--------------------

Descriptive data are presented with frequency and percentage or as means with standard deviation (SD). All statistical analyses were performed using Microsoft Office Excel 2007.

Results {#Sec8}
=======

Over the 10-week period, three pharmacists and two pharmacy residents of the CPU analyzed 1989 prescriptions of injectable antineoplastic involving 5284 preparations for 759 patients in inpatient units or outpatient units. Among them, 200 prescriptions (10.1%) relating to 185 patients had DRPs leading to 237 PIs. Patients concerned by DRPs were of mean age 63.5 ± 13.7 years, mainly male and had solid tumors (Table [1](#Tab1){ref-type="table"}). Table 1Characteristics of patients with DRP (*n* = 185)Patients characteristicsn (%)Age, mean (SD)**63.5 (13.7)**Sex (male)**100 (54.1)Diagnosis** **Solid tumor150 (81.1)**  Breast Cancer26 (14.1)  Colorectal cancer26 (14.1)  Non-small cell lung cancer22 (11.9)  Head and neck cancer21 (11.4)  Ovarian cancer10 (5.4)  Cancer of the pancreas8 (4.3)  Neuroendocrine cancer8 (4.3)  Bladder cancer5 (2.7)  Small cell lung cancer5 (2.7)  Cervical cancer4 (2.2)  Oesophageal cancer4 (2.2)  Glioma2 (1.1)  Sarcoma2 (1.1)  Thymus carcinoma2 (1.1)  Anal cancer1 (0.5)  Astrocytoma1 (0.5)  Biliary cancer1 (0.5)  Gastric cancer1 (0.5)  Prostate cancer1 (0.5) **Hematologic disease35 (18.9)**  Non Hodgkin lymphoma11 (6.0)  Multiple myeloma8 (4.3)  Acute leukemia7 (3.9)  Hodgkin lymphoma3 (1.6)  Myelomonocytic leukemia2 (1.1)  Chronic lymphocytic leukemia1 (0.5)  Glanzmann thrombasthenia1 (0.5)  Hairy cell leukemia1 (0.5)  Idiopathic thrombocytopenic purpura1 (0.5)

Drug-related problems AND nature of the pharmacist interventions {#Sec9}
----------------------------------------------------------------

DRPs mainly concerned dosages: 41.4% (*n* = 98) were a supra-therapeutic dosage and 15.2% (*n* = 36) a sub-therapeutic dosage (Table [2](#Tab2){ref-type="table"}). The causes of supra-therapeutic dosages were mainly failure to make dose reductions due to toxicity and overestimations of patient's weight. Sub-therapeutic dosages were often related to a failure to update of serum creatinine level in the dose calculation of Carboplatin and also errors in patient's weight. In 12.2% of cases (*n* = 29), a parameter was missing for analyzing the prescription; in such cases monitoring or an update of monitoring (e.g. creatinine clearance) was requested to the prescriber. For 11.0% (*n* = 26), the DRP was related to non-conformity with the guidelines, e.g. the prescribed therapeutic protocol did not correspond to the correct protocol, the previously prescribed chemotherapy regimen or the regimen recommended for the patient at the last multidisciplinary cancer board. Untreated indications concerned 9.7% of PIs (*n* = 23); this problem being due to the lack of prescription for a patient or the absence of a drug in the prescribed protocol. The PIs were: dose adjustment (52.7%), drug switch request (15.2%), drug addition (9.7%), drug monitoring (9.3%), drug discontinuation (8.0%), and administration mode optimization (5.1%) (Table [2](#Tab2){ref-type="table"}). Table 2Types of DRPs and PIsDrug related problemsn (%)Supratherapeutic dosage98 (41.4)Subtherapeutic dosage36 (15.2)Drug monitoring29 (12.2)Non-conformity to guidelines26 (11.0)Untreated indication23 (9.7)Inappropriate timing of administration9 (3.8)Drug without indication7 (3.0)Contra-indication4 (1.7)Improper administration2 (0.8)Adverse drug reaction1 (0.4)Non-conformity of the drug choice compared to the Formulary1 (0.4)Treatment not received1 (0.4)**Interventions** Dose adjustment125 (52.7) Drug switch36 (15.2) Addition of a new drug23 (9.7) Drug monitoring22 (9.3) Drug discontinuation19 (8.0) Administration mode optimization12 (5.1)**Total237 (100)**

The main injectable antineoplastics involved in DRP were: Carboplatin (*n* = 38), Cisplatin (*n* = 36) and Fluorouracil (*n* = 28) (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Anatomical Therapeutic Chemical (ATC) classification of chemotherapy drugs involved in Drug Related Problems

Most PIs (*n* = 179; 75.5%) were accepted by prescribers (refusal rate: 24.5%).

CLINICAL, ECONOMIC AND ORGANIZATIONAL IMPACT OF PIs {#Sec10}
---------------------------------------------------

The multidimensional impact was determined for 237 PIs using the CLEO tool.

Overall, 21 PIs (8.9%) were considered to have had a major clinical impact, which could prevent hospitalization, the prolongation of hospitalization or permanent disability. Experts determined that neurological, hematological, renal, gastrointestinal and skin toxicities were avoided, but no PI was considered to have avoided a lethal accident. The list of these 21 PIs were summarized in Table [3](#Tab3){ref-type="table"}. The majority of these PIs required dose adjustment. All PIs with major clinical impact were accepted by the prescribers. Experts considered that 49 PIs (20.7%) had a moderate clinical impact, which could prevent harm that would have required further monitoring or treatment, 62 PIs (26.2%) had a minor clinical impact that would have required further monitoring/treatment. While 95 PIs (40.0%) had no clinical impact, the panels considered 9 PIs out of 237 (3.8%) as potentially harmful; these PIs were all rejected by prescribers. For one PI (0.4%) the clinical impact was not determined because the committee had insufficient available information (Fig. [3](#Fig3){ref-type="fig"}). Table 3Description of PIs with a major clinical impact (*n* = 21)UnitDRPDrug(s)PIDescriptionEconomic impactOrganizational impactHepato-gastro enterology day care unitNon conformity to guidelines**PanitumumabDrug switch**Course number 1: Prescription VECTIBIX / FOLFOX instead of AVASTIN FOLFOX (RAS analysis in progress)10Hepato-gastro enterology day care unitNon conformity to guidelines**PanitumumabDrug switch**Course number 1: Prescription VECTIBIX / FOLFOX instead of AVASTIN FOLFOX (RAS analysis in progress)10Oncology day care unitNon conformity to guidelines**GemcitabineDrug discontinuation**Prescription signed and green light given for gemcitabine but course should be canceled due to thrombocytopenia11Radiotherapy day care unitNon conformity to guidelines**CisplatinDose adjustment**Overdose: Prescription cisplatin 60 mg / m^2^ for 2 days, while the patient should not receive cisplatin on day 211Pneumology day care unitContra indication**CisplatinDrug discontinuation**Prescription of an adjuvant cisplatin course for a patient having a clearance of creatinine 43 ml/min according to the CKD EPI formula11Oncology day care unitUntreated indication**TrastuzumabAddition of a new drug**Error in the protocol: missing one line in protocol on Taxotere Cyclophosphamide Trastuzumab01Oncology day care unitUntreated indication**TrastuzumabAddition of a new drug**Error in the protocol: missing one line in protocol on Taxotere Cyclophosphamide Trastuzumab01Hepato-gastro enterology day care unitSupra-therapeutic dosage**FluorouracileOxaliplatinDose adjustment**Reductions of 50% of in 5 fluorouracil (5FU) and of 80% in oxaliplatin omitted in a patient with toxicileitis to 5 FU in his medical records10Oncology day care unitSupra-therapeutic dosage**CetuximabDose adjustment**Expected reduction cetuximab 200 mg / m^2^ instead of 500 mg / m^2^ not appliedToxicity during previous treatments: folliculitis, xerosis11Oncology day care unitSupra-therapeutic dosage**CyclophosphamideDoxorubicineCisplatineDose adjustment**Expected reductions of 80% for Cyclophosphamide and doxorubicin and of 66% for cisplatin omitted. During the intercure period: anemia, thrombocytopenia, non-febrile agranulocytosis, oedematous decompensation leading to emergency consultation11Oncology day care unitSupra-therapeutic dosage**IrinotecanDose adjustment**Reduction of 80% for irinotecan omittedDuring the intercure period: Hospitalization for diarrhea during previous course11Oncology day care unitSupra-therapeutic dosage**PaclitaxelDose adjustment**Expected reduction to 80% paclitaxel not appliedToxicity: paresthesia of hands and feet prior to paclitaxel11Oncology day care unitSupra-therapeutic dosage**CabazitaxelDose adjustment**Expected reduction to 80% for carbazitaxelHospitalization during previous course for deterioration in general condition and nausea11Oncology day care unitSupra-therapeutic dosage**PaclitaxelDose adjustment**Expected reduction of 80% for paclitaxel omittedToxicity: Feet paresthesia prior to paclitaxel11Oncology day care unitSupra-therapeutic dosage**PaclitaxelDose adjustment**Expected reduction of 80% paclitaxel not appliedToxicity: Hands and feet paresthesia prior to paclitaxel11Oncology day care unitSupra-therapeutic dosage**PaclitaxelDose adjustment**Expected reduction of 80% for paclitaxel not appliedToxicity during previous treatments: Neuropathy11Oncology day care unitSupra-therapeutic dosage**DocetaxelDose adjustment**Expected reduction of 66% for not appliedToxicity during intercure: Edema of the lower limbs11Oncology day care unitSupra-therapeutic dosage**VinorelbineDose adjustment**Prescription of weekly navelbine at dosage of 25 mg / m^2^Medical history: Neutropenia grade IV with a weekly navelbine protocol11Oncology day care unitSupra-therapeutic dosage**VinorelbineDose adjustment**Expected reduction of 80% for navelbineToxicity during intercure: Hospitalization for general condition alteration and febrile peak11Oncology day care unitSupra-therapeutic dosage**GemcitabineDose adjustment**Expected reduction of 80% for gemcitabine not appliedToxicity during previous treatment: Febrile neutropenia11Oncology day care unitSupra-therapeutic dosage**CisplatinFluorouracileDose adjustment**Course number 1: expected reductions because of asthenia and undernutrition by 80% for cisplatin and fluorouracile not applied11 Fig. 3Clinical impact of Pharmacist's Interventions

Regarding organizational impact, 165 PIs (67.5%) were evaluated as having a positive impact on the quality of patient management, and 71 (30.0%) and 6 PIs (2.5%) as having a null or unfavorable impact, respectively. Forty-one PIs were considered as having no clinical or economic impact but only a favorable organizational impact. These PIs most often concerned a date or hospitalization unit errors. These changes were requested in order to facilitate the work of healthcare providers in charge of the patient, allowing them to see the prescription at the right date for the correct care unit and authorizing them to validate electronically the administration of the chemotherapy.

Concerning economic aspects, according to the expert assessment using the CLEO tool, 105 PIs (44.3%) were assessed as having a positive impact (resulted in reduced cost of antineoplastic drugs), 94 PIs (39.7%) had null economic impact and 38 PIs (16.0%) a negative economic impact (increasing the cost of antineoplastic drugs). PIs accepted by prescribers with negative economic impact increased the direct drug costs by 11,878 € and PIs accepted by prescribers with positive economic impact represented a saving of 15,096 € (Table [4](#Tab4){ref-type="table"}). Table 4Classification of Economic Impact and Quantifying of Cost SavingEconomic impactNumber of interventions (%)Costs−1: Negative38 (16.0)11, 878 €0: Null94 (39.7)0 €+ 1: Positive105 (44.3)15,096 €**Total benefit3218 €**

Through pharmaceutical analysis, the final cost saving was of 3218 € over the study period. Drug cost saving for a year would thus be 16,731 € for our hospital. For PIs accepted by prescribers and having a positive economic impact, the average saving per accepted PI was 181 ± 451 €, ranging from 0 € to 2019 € (median: 5.3 €; IQR: 15.9 €). These PIs were related to dose adjustments (*n* = 61), drug switch requests (*n* = 11) and drug discontinuations (*n* = 10). For PIs accepted by prescribers having a negative economic impact, the average additional cost per accepted PI was 439 ± 835 €, ranging from 0 € to 3262 € (median: 21.9 €; IQR: 507.2 €). These PIs were related to dose adjustments (*n* = 15), drug additions (n = 6), drug switch requests (*n* = 5) and administration mode optimization (n = 1).

PIs with a major, moderate and minor clinical impact predominantly had a positive economic impact with respectively 90.5, 69.4 and 50.0% positive economic impact (Fig. [4](#Fig4){ref-type="fig"}). No PI with major clinical impact had a negative economic impact. Seventy-three PIs had no clinical and economic impact, nevertheless 42 of them (57.5%) had a positive organizational impact (Fig. [4](#Fig4){ref-type="fig"}). Finally, few PIs (12.7%) had no impact on the 3 dimensions. Fig. 4Combination of clinical and economic impact levels of PIs

Discussion {#Sec11}
==========

This study shows that DRPs are commonly encountered in injectable antineoplastic prescriptions. PIs related to DRPs significantly improve prescriptions in terms of clinical, economic and organizational dimensions: 55.8% of PIs had a positive clinical impact, 67.5% PIs had a positive impact on patient management from the healthcare providers' perspective and a cost saving of 3218 € on drugs was realized over the study period.

Findings {#Sec12}
--------

Previous studies have reported PIs as being needed for 1.5 to 27.6% of injectable antineoplastic prescriptions \[[@CR20]--[@CR24]\]. This wide range can be explained by organizational differences: in a center without computerized prescriptions, 27.6% of prescriptions required a PI \[[@CR24]\]. A DRP rate of 3.0% was found in an establishment in which prescriptions were based on standardized pre-printed prescriptions and a listing of protocols \[[@CR22]\]. Recent studies in settings with CPOE found a PI rate lower than 2% \[[@CR20], [@CR21]\]. In our study, the PI rate of 10.1% was quite high despite computerized prescriptions and use of protocols. A large proportion of prescriptions established by residents in medicine and the lack of update of creatinine values in the CPOE system may explain this finding.

Our results confirm those of previous studies which showed that overdosages and under-dosages are the most frequently encountered problems \[[@CR20], [@CR21], [@CR24]\]. Consequently, in more than half of cases, PIs requested a dose adjustment. Monitoring problems is the third most commonly encountered DRP, mainly related to creatinine value updates required for platinum compounds. In agreement with previous studies, most PIs were formulated for two drugs: Carboplatin (*n* = 39) and Cisplatin (*n* = 36) \[[@CR22]\]. This result can be explained by the risk of renal toxicity of platinum compounds requiring regular dose adjustment or leading to contra-indication.

In our study, PIs were accepted by senior physicians and medicine residents in 75.5% of the cases. This acceptance rate is close to that usually observed in cancerology and in others areas of clinical pharmacy \[[@CR21], [@CR25]\].

This study shows that the pharmaceutical analysis of injectable antineoplastic prescriptions has a positive clinical impact: 55.8% of PIs were considered to have a positive clinical impact. Our results are in accordance with the literature, even if the use of different tools does not allow us to directly compare our results with the previous studies. Knez et al. found that 48% of PIs involving injectable antineoplastic prescriptions were clinically very significant, another study in a large chemotherapy preparation unit reported that 50.4% of PIs were considered to be clinically significant \[[@CR8], [@CR23]\].

In our study, no PI was considered to have avoided a potentially lethal effect for the patient, while some other studies have reported PIs performed by pharmacists in a CPU that potentially avoided patient death \[[@CR21], [@CR23], [@CR26]\]. In these studies, PIs with life-saving impact were essentially related to overdose prescription problems of 3-to 50-fold the theoretical doses or cases of co-prescription. During the period studied in our hospital there was no case of such large overdosage as that reported elsewhere, possibly due to safer procedures including computerized prescriptions and standardized protocols.

Our choice of using the CLEO tool enabled us to identify PIs with a negative clinical impact. Nine PIs were considered by the expert panels to have a negative clinical impact. For 5 of them, the inappropriateness of the PI was due to changes in patient's clinical status that had not been saved into the electronic medical record system and therefore was unknown to pharmacists before their intervention.

Our study suggests that the pharmaceutical analysis of injectable antineoplastic prescriptions has a positive economic impact from hospital's perspective by reducing direct drug costs: 44.3% of PIs decreased the cost of patient's therapeutic management. These results are in accordance with previous studies \[[@CR27]--[@CR29]\]. In a study conducted in another French university hospital, focusing on the pharmaceutical analysis of injectable antineoplastic prescriptions, Nerich et al. found that 31.7% of PIs reduced direct drug costs \[[@CR27]\]. In the same study, it was estimated that 1459 PIs carried out over a one-year period generated a saving of 25,136 € from hospital's perspective. In our University Hospital, we estimated that savings would be 16,731 € over a year, somewhat less. However, it is difficult to compare results between these two studies, because the cost assessment is based on the purchase prices of injectable antineoplastic drugs, which differs between hospitals and over time. In our study, we assumed that a PI had an economic impact on a single course of chemotherapy, whereas other studies extrapolated the impact of a PI beyond a single course of the drug. Even taking the shortest chronological impact, pharmaceutical analysis of injectable antineoplastics is associated with a positive economic impact \[[@CR30]\]. In another French study, the authors estimated that, over a year, chemotherapy-related drug errors could have resulted in an additional 216 days of hospitalization, and cost avoidance related to hospitalization and medication was estimated at 92,907€ if these errors had not been detected by pharmaceutical analysis \[[@CR26]\].

A majority (67.5%) of PIs had a positive organizational impact. These PIs included changes in the date of prescription or in the hospital unit, and minimal dose adjustments. They were considered as having a positive organizational impact because the quality of the prescription was improved. For example in our organization, the CPOE automatically propose a date of prescription according to the date of the previous injection. If the next injection must be postponed by many days, the prescriber must manually modify the date proposed. If the date is not modified, the prescription will appear on the date originally planned. Despite the use of CPOE prescription errors remain persistent, this is a well-known problem, including for antineoplastics \[[@CR31]--[@CR33]\]. To our knowledge no other study took into account the organizational impact of PIs for healthcare providers. However, organizational impact was the most difficult of the three dimensions to assess, because of the many different indicators of care management (time savings, improved security, knowledge, job satisfaction, continuity of care etc.) and the need to take into account the different points of view of the various healthcare professionals (physicians, pharmacists, nurses).

Strength and limitations {#Sec13}
------------------------

To the best of our knowledge, this is the first study describing the impact of PI for injectable antineoplastic prescriptions in a multidimensional way. Most tools focus on clinical outcomes and/or cost savings. However, some PIs that have no direct clinical or economic impact can benefit for the healthcare practitioners, for example, a PI that improves safety for nurses (e.g., the pharmacist suggests a change in the dosage form such that the nurse does not have to manipulate potentially toxic drugs). The organizational dimension of the CLEO tool aims to detect such effect. One could use all three dimensions, with a three-component code describing the entire impact of a PI.

As the CLEO tool does not quantify savings or additional costs, for the economic evaluation we used a complementary approach limited to the direct costs of drugs. The experts (specialist physicians and pharmacists) determined that, in some cases, neurological, hematological, renal, gastrointestinal and skin toxicities were avoided but the costs of treatments or additional days of hospitalization that would have been needed to manage these adverse drug events were not assessed.

Conclusion {#Sec14}
==========

Pharmaceutical analysis of injectable antineoplastic prescriptions in a CPU is complementary of clinical pharmacy activities performed in oncology and hematology care units. Our study shows that pharmaceutical analysis of injectable antineoplastic prescriptions has clinical, economic and organizational impacts. The involvement of pharmacists reduces medication errors, some of which could have serious consequences for oncology patients due drugs toxicity. In a large hospital the centralization of the pharmaceutical analysis of injectable antineoplastic prescriptions presents additional economic and organizational interests, leading to PIs for dose adjustments, drug switches, or drug discontinuations that reduce the direct costs of drug management. The evaluation of this activity should be regularly conducted to assess the added value of pharmacists in improving quality of care for patients and for healthcare system and could also be used as indicator of pharmacist's performance.
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